Brian Bronk joined the Sanofi Global Business Development organization in January 2017 when he assumed the role of Head of External Innovation for Rare Diseases. He and his team are responsible for orchestrating the pursuit of external innovation solutions that contribute to the Rare Disease R&D portfolio and in concert with the cohesive and integrated business and scientific strategy set with the therapeutic area. Prior to the role in Rare Diseases, Brian was a member of the Sunrise team, part of Global R&D at Sanofi.
Before joining Sanofi, Brian had been advising a number of venture capital groups and privately held life science organizations, providing input on topics ranging from research and development operations and strategy to business and corporate development. In this role, his efforts contributed to a number of successful financing rounds, as well as advancing R&D portfolios through key milestones. During his time as an independent advisor, Brian also co-founded and successfully launched Armada Therapeutics.
From 2009-2013, Brian was Vice President of Research and Development at Satori Pharmaceuticals, where he was a member of the Executive Leadership team and led the internal and external chemical sciences and drug metabolism groups. Before Satori, Brian was at Pfizer (1994-2008), rising to the level of Senior Director of Chemistry, leading groups in both Infectious Disease and Neuroscience. During his time at Pfizer, his responsibilities included contributing to R&D strategy across multiple platforms and therapeutic areas. By focusing on innovation and collaboration, Brian and his teams have been involved in the discovery of more than twenty development candidates, including the launched products Draxxin™, Convenia™, Cerina™ and Slentrol™